Arthritis Research & Therapy · 2017 · 11 citations · 24 references
MedicinePharmacologyPharmacotherapyPharmacogeneticsPharmacogenomicsRheumatologyGenome-wide Association StudiesGenotype-phenotype Association AnalysisPharmacogenetic TestingDrug Response PhenotypesDrug Response VariabilityHeritability Estimation From Association DataHeritable Disease SusceptibilityHeritable Phenotype CharacterizationLongitudinal Cohort AnalysisPharmacogenetic StudiesWhole-genome Sequencing Analysis
BACKGROUND: An individual patient's response to a particular drug is influenced by multiple factors, which may include genetic predisposition. Pharmacogenetic studies attempt to discover and estimate the contributions of genetic variants to the variability in response to a drug treatment. The task of identifying the genetic contribution is often complicated by response phenotypes that are based on imprecise or subjective clinical observations. Because the success of a pharmacogenetic study depends on the analysis of a heritable phenotype, it is important to identify phenotypes with a significant heritable component to ensure reliable and reproducible results in subsequent genetic association studies. METHODS: We retrospectively analyzed data collected from 436 rheumatoid arthritis patients treated with golimumab during the phase III GO-FURTHER study. We investigated the reliability of several potential response outcomes after golimumab treatment. Using whole-genome sequencing of the clinical trial cohort, we estimated the heritability of each potential outcome measure. We further performed a longitudinal analysis of the clinical data to estimate variability of outcome measures over time and the degree to which each response metric could be confounded by placebo response. RESULTS: We determined that the high degree of within-patient variation over time makes a single follow-up visit insufficient to assess an individual patient's response to golimumab treatment. We found that different potential response outcomes had varying degrees of heritability and that averaging across multiple follow-up visits yielded higher heritability estimates than single follow-up estimates. Importantly, we found that the change in swollen and tender joint counts were the most heritable outcome metrics we tested; however, we showed that they are also more likely to be confounded by a placebo response than objective phenotypes like the change in C-reactive protein levels. CONCLUSIONS: Our rigorous approach to finding robust and heritable response phenotypes could be beneficial to all pharmacogenetic studies and may lead to more reliable and reproducible results. TRIAL REGISTRATION: Clinicaltrials.gov NCT00973479 . Registered 4 September 2009.
24
R: A Language and Environment for Statistical Computing
R Core Team · 2000 · 353K citations · Full text
Natural Sciences, Computer Science, Statistical Computing +10
Daniel Aletaha, Tuhina Neogi, Alan J. Silman et al. · Arthritis & Rheumatism · 2010 · 9.6K citations · Full text
Medicine, Internal Medicine, Clinical Classification Systems +13
GCTA: A Tool for Genome-wide Complex Trait Analysis
Jian Yang, Sang Lee, Michael E. Goddard et al. · The American Journal of Human Genetics · 2010 · 9.3K citations · Full text
M.L.L. Prevoo, Martin A. van't Hof, H. H. Kuper et al. · Arthritis & Rheumatism · 1995 · 6.2K citations